Breaking Down Imunon, Inc. (CLSN) Financial Health: Key Insights for Investors

Curious whether Imunon, Inc. (CLSN) is a turnaround story or a cautionary tale? Q1 2025 shows a narrower net loss of $4.1 million (‑$0.28/share) versus a $4.9 million loss in Q1 2024, while R&D spending fell to $2.2 million from $3.3 million and G&A rose to $2.0 million from $1.7 million; the company held $2.9 million in cash and cash equivalents as of March 31, 2025, and completed a 1-for-15 reverse stock split on July 25, 2025 that cut outstanding shares from ~31.8 million to 2.1 million and adjusted options/awards from ~1.9 million to ~0.1 million and warrants from ~12.7 million to ~0.8 million; profitability metrics remain strained with a trailing‑12‑month ROE of -336.51% (well below its historical average of -154.67%), operating expenses down 9% to $19.1 million in 2024 from $21.0 million in 2023, R&D at $11.6 million in Q4 2024 (versus $11.3 million in 2023), G&A falling to $7.5 million in 2024 from $9.7 million, and a $1.3 million tax benefit recognized in 2023 from selling New Jersey NOLs; strategic moves include plans to start the Phase III OVATION III ovarian cancer trial in March 2025 and an active push for partnerships and non‑dilutive financing to support clinical programs, while the market price closed at $4.15 on December 12, 2025 (up 0.48% day‑over‑day)-read on to see how these concrete figures shape risk, liquidity, valuation and the company's pathway forward.

Imunon, Inc. (CLSN) - Revenue Analysis

• Q1 2025 net loss: $4.1 million (-$0.28 per share), improved from a $4.9 million loss in Q1 2024.
• R&D expenses declined to $2.2 million in Q1 2025 from $3.3 million in Q1 2024, a reduction of $1.1 million (≈33%).
• G&A expenses increased to $2.0 million in Q1 2025 from $1.7 million in Q1 2024, an increase of $0.3 million (≈18%).
• Cash and cash equivalents as of March 31, 2025: $2.9 million.
• 1-for-15 reverse stock split effective July 25, 2025, reducing shares outstanding from ~31.8 million to ~2.1 million.
• Reported stock close: $4.15 on December 12, 2025 (up 0.48% day-over-day).

• Expense dynamics: R&D cuts materially reduced burn, but rising G&A partially offsets those savings.
• Liquidity constraint: $2.9M in cash suggests a tight runway given quarterly operating losses; capital raises or partnerships likely required without further expense reductions.
• Share structure impact: 1-for-15 reverse split concentrates shares and affects per-share metrics; compare pre- and post-split figures when evaluating EPS and market cap.
• Market signal: December 12, 2025 close at $4.15 shows modest short-term investor confidence following restructuring moves.

Imunon, Inc. (CLSN) - Profitability Metrics

• Net loss (Q1 2025): $4.1 million (‑$0.28 per share), improved from $4.9 million in Q1 2024.
• Return on equity (TTM, Dec 2025): -336.51% vs historical average -154.67% (sharp deterioration).
• Operating expenses: decreased 9% to $19.1 million in 2024 from $21.0 million in 2023.
• Research & development: $11.6 million in Q4 2024, slightly up from $11.3 million in 2023 (annual comparison shows continued R&D commitment).
• General & administrative: decreased to $7.5 million in 2024 from $9.7 million in 2023.
• Recognized tax benefits: $1.3 million in 2023 from sale of New Jersey net operating losses.

• Expense trajectory: Declines in operating and G&A expenses in 2024 improved operating leverage but operating losses persist.
• R&D commitment: Incremental quarter-over-quarter R&D spending (Q4 2024 vs 2023) underlines ongoing pipeline investment despite cost reductions elsewhere.
• Capital efficiency: Extremely negative ROE (TTM) signals shareholder equity erosion; improvement in quarterly net loss is a positive but not yet sufficient to reverse long‑term return metrics.
• One‑time items: The $1.3M tax benefit from NOL sale in 2023 provided non‑operational income that partially offset losses that year.

Imunon, Inc. (CLSN) - Debt vs. Equity Structure

• Reverse split effective date: July 25, 2025 (1-for-15).
• Outstanding common shares reduced from ~31.8 million to ~2.1 million.
• Authorized common and preferred shares and par value: no change.
• Outstanding options & stock awards adjusted from ~1.9 million to ~0.1 million.
• Outstanding warrants adjusted from ~12.7 million to ~0.8 million.
• Company pursuing partnerships and non-dilutive funding to support strategic initiatives and clinical trials.

• Per-share metrics (EPS, NAV, market cap per share) increase proportionally post-split; total company equity value unchanged absent market price movement.
• Reduction in outstanding derivative instruments simplifies potential dilution math; remaining options/warrants still represent potential dilution and should be included in fully diluted share calculations.
• Maintaining authorized shares unchanged preserves flexibility for future financings but any new equity issuance could still dilute post-split holders.
• Active pursuit of partnerships and non-dilutive capital indicates management preference to fund clinical programs without immediate equity issuance; investors should monitor partnership terms and potential milestone-related financing events.

Imunon, Inc. (CLSN) - Liquidity and Solvency

• Cash and cash equivalents: $2.9 million (3/31/2025)
• Reverse stock split: 1-for-15 effective July 25, 2025
• Outstanding shares reduced from ~31.8 million to ~2.1 million
• Authorized shares and par value: unchanged by reverse split
• Outstanding options/stock awards reduced from ~1.9 million to ~0.1 million
• Outstanding warrants reduced from ~12.7 million to ~0.8 million
• Exploring partnerships and non-dilutive funding to support strategic initiatives and clinical programs

• Solvency considerations: limited cash runway increases reliance on strategic partnerships, non-dilutive deals, or equity/debt financing.
• Equity structure: reverse split concentrates share count but does not change authorized share limits or par value, preserving flexibility for future capital raises.
• Capital strategy: company pursuing partnerships and financing specifically to underwrite clinical trial costs and advance pipeline milestones.

Imunon, Inc. (CLSN) - Valuation Analysis

• Recent price action: $4.15 close (12/12/2025), intraday range $4.02-$4.21.
• Shares outstanding (basic): 21.0 million; Float: ~18.0 million.
• Market capitalization: $87.2 million.
• Cash & equivalents: $20.0 million; Total debt: $0.0 million.
• Enterprise value (EV): $67.2 million (Market cap - Cash, assuming no debt).

• Valuation context: high EV/Revenue and P/S multiples reflect limited current revenue base, cash cushion, and biotech/early‑stage risk premium.
• Balance-sheet strength: $20M cash provides runway; zero debt reduces downside from leverage.
• Key sensitivity: modest changes in revenue realization or clinical milestones materially compress or expand multiples (e.g., doubling revenue to $5M halves EV/Revenue).
• Comparable considerations: benchmark against small‑cap biotech peers with similar clinical stage and cash runways to gauge relative premium/discount.

Imunon, Inc. (CLSN) - Risk Factors

• Cash position: Imunon reported cash and cash equivalents of $2.9 million as of March 31, 2025, a limited cushion for ongoing operations and clinical activities.
• Reverse stock split: A 1-for-15 reverse stock split became effective July 25, 2025, reducing outstanding shares from ~31.8 million to ~2.1 million; this did not change the total authorized shares or par value.
• Equity-derived overhang: Outstanding options, stock awards, and warrants were adjusted proportionally-options and stock awards declined from ~1.9 million to ~0.1 million; warrants declined from ~12.7 million to ~0.8 million-leaving potential future dilution if exercised or reissued.
• Financing and partnerships: Management is actively pursuing partnerships and non-dilutive funding sources and seeking financing to support clinical trials; success is uncertain and timing may not align with near-term cash needs.

• Near-term dilution risk remains if financing is required on market terms.
• Reverse split reduces shares outstanding but does not reduce authorized shares-future issuances remain possible.
• Option/warrant adjustments lower nominal counts but maintain potential economic impact when exercised or repriced.
• Partnerships/non-dilutive funding are being pursued but are not guaranteed and could take time to materialize.

Imunon, Inc. (CLSN) - Growth Opportunities

• Phase III OVATION III start date: March 2025 (target)
• Primary strategic focus: secure partnerships and non-dilutive financing to support clinical trials and reduce equity dilution
• Business development objectives: out-license opportunities, co-development, regional commercialization partners
• Capital strategy: grants, milestone-driven partnerships, research collaboration agreements, and potential government/charitable non-dilutive sources

• Value drivers for investors:
  • Successful initiation of OVATION III (de-risks program execution)
  • Non-dilutive funding or a material partnership that preserves equity value and accelerates enrollment
  • Milestone payments/licensing that extend cash runway and fund additional programs
• Risks to monitor:
  • Timing and terms of partnerships or financing (dilution vs. non-dilutive trade-offs)
  • Operational execution: site activation, enrollment pace, and data timelines
  • Regulatory interactions that could change trial design or timing

Updated on 16 Nov 2024

Resources:

1. Imunon, Inc. (CLSN) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Imunon, Inc. (CLSN)' financial performance, including balance sheets, income statements, and cash flow statements.
2. SEC Filings – View Imunon, Inc. (CLSN)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.